3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
10
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Interventions
pembrolizumab
45
Specimen Handling
45
Biopsy
37
Magnetic Resonance Spectroscopy
36
Paclitaxel
22
Nivolumab
21
Carboplatin
21
Gemcitabine
20
Radiosurgery
18
Irinotecan
16
Ipilimumab
13
Cisplatin
13
Capecitabine
12
130-nm albumin-bound paclitaxel
12
trastuzumab deruxtecan
11
Taxes
11
Pemetrexed
11
Cetuximab
11
olaparib
10
Leucovorin
10
Fluorouracil
10
Cyclophosphamide
10
durvalumab
9
Oxaliplatin
9
Bevacizumab
9
abemaciclib
8
X-Rays
8
Fulvestrant
8
Drug Therapy
8
palbociclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Ado-Trastuzumab Emtansine
×
90 days
×
Clear all
NCT06663787
2026-05-13
HER2 CR
Nagoya City University
Active not recruiting
50 enrolled